Volume 28, Number 4—April 2022
Research
Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination
Table
Characteristics of participants in a study of immune response against variants of concern in dialysis patients 4 months after SARS-CoV-2 mRNA vaccination*
Characteristic | Nondialysis control group | Hemodialysis group | p value for difference between groups |
---|---|---|---|
No. (%) patients |
23 (100) |
76 (100) |
NA |
Median age, y (IQR) |
55 (14) |
70.5 (18.25) |
2.78 × 10−9 |
Sex | 1.01 × 10−2† | ||
M | 6 (26.09) | 43 (56.58) | |
F |
17 (73.91) |
33 (43.42) |
|
Median days since start of hemodialysis (IQR) |
NA |
1,337 (1,686.5) |
NA |
Using immunosuppressive medication |
0 |
10 (13.16) |
6.77 × 10−2 |
Underlying condition | |||
Obesity, BMI >30‡ | 4 (17.39) | 16 (21.05) | 8.68 × 10−1 |
Diabetes mellitus | 0 | 19 (25) | 7.30 × 10−3 |
Cardiovascular disease | 0 | 35 (46.05) | 2.93 × 10−5 |
*Values are no. (%) except as indicated. Percentages are for total group. BMI, body mass index; IQR, interquartile range; NA, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †p value reflects difference in male-to-female ratios between the two groups, not differences explicitly for either male or female persons. ‡BMI for 1 person was not known.
1These authors contributed equally to this article.
2These authors contributed equally to this article.
Page created: December 28, 2021
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.